

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU578409255US, in an envelope addressed to: Box Non-Fee Amendment, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: March 4, 2003

Signature:

(Monica L. Thomas)

Docket No.: HO-P01961US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Patent Application of:
Sue J. Kenwrick, et al

Application No.: 09/863,049

Group Art Unit: 1632

Filed: May 22, 2001

Examiner: Wehbe, A.M.S.

For: DIAGNOSIS AND TREATMENT OF
MEDICAL CONDITIONS ASSOCIATED
WITH DEFECTIVE NFKAPPA B(NF-
KAPPAB) ACTIVATION

SECOND PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Pursuant to the Action mailed January 30, 2003 and the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Applicants submit herewith this Second Preliminary Amendment and the accompanying Amended Sequence Listing.


Prior to examination on the merits, please amend the above-identified U.S. patent application as follows:

In the Specification

On page 63, the paragraph beginning on line 28, please replace the following paragraph:

DNA from a male abortus with an IP haplotype and NEMO rearrangement from family IP1 (Jouet et al) was digested with *Eco RI* and purified by ethanol precipitation. 750 pmoles of Adapter primers Eco adapt1 (5'-CTAATACGACTCACTATAGGGCTCGAGCAGCCTCCGAGGGCAG-3'; SEQ ID

25261002.1



RECEIVED
MAR 19 2003
TECH CENTER 1600/2900

B1